Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Neumora Therapeutics Inc (NMRA)

Neumora Therapeutics Inc (NMRA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 412,710
  • Shares Outstanding, K 167,089
  • Annual Sales, $ 0 K
  • Annual Income, $ -243,790 K
  • EBIT $ -246 M
  • EBITDA $ -251 M
  • 60-Month Beta 2.49
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.08

Options Overview Details

View History
  • Implied Volatility 192.70% (-55.18%)
  • Historical Volatility 92.26%
  • IV Percentile 50%
  • IV Rank 26.04%
  • IV High 604.03% on 04/16/25
  • IV Low 47.87% on 09/03/25
  • Expected Move (DTE 23) 0.77 (30.97%)
  • Put/Call Vol Ratio 0.02
  • Today's Volume 50
  • Volume Avg (30-Day) 311
  • Put/Call OI Ratio 0.68
  • Today's Open Interest 22,792
  • Open Int (30-Day) 21,854
  • Expected Range 1.71 to 3.24

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.34
  • Number of Estimates 4
  • High Estimate -0.32
  • Low Estimate -0.37
  • Prior Year -0.37
  • Growth Rate Est. (year over year) +8.11%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.41 +2.49%
on 03/24/26
3.60 -31.39%
on 02/27/26
-0.96 (-27.99%)
since 02/24/26
3-Month
1.50 +64.67%
on 01/06/26
3.65 -32.33%
on 02/18/26
+0.66 (+36.46%)
since 12/24/25
52-Week
0.61 +304.26%
on 05/14/25
3.65 -32.33%
on 02/18/26
+1.27 (+105.83%)
since 03/24/25

Most Recent Stories

More News
NMRA Investors Have Opportunity to Join Neumora Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Neumora Therapeutics, Inc. (“Neumora” or “the Company”)...

NMRA : 2.47 (unch)
Neumora Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Monday, March 30, 2026

WATERTOWN, Mass., March 16, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that target...

NMRA : 2.47 (unch)
Neumora Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026

WATERTOWN, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that target...

NMRA : 2.47 (unch)
Neumora Therapeutics Highlights 2026 Pipeline Strategy and Anticipated Upcoming Milestones

Multiple clinical data readouts expected in 2026 present opportunity for substantial value creation KOASTAL-2 and -3 on track for consolidated topline readout in the second quarter of 2026 Plans...

NMRA : 2.47 (unch)
Neumora Therapeutics Announces Positive Results from NMRA-511 Phase 1b Signal-Seeking Study in Alzheimer’s Disease Agitation

NMRA-511 demonstrated a 15.7 reduction on mean CMAI total score, representing a clinically meaningful effect  NMRA-511 demonstrated unsurpassed clinical effect size on CMAI total score in a pre-specified...

NMRA : 2.47 (unch)
Neumora Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Announced class-leading data from diet-induced obesity (DIO) mouse model with NMRA-215, a potentially best-in-class, highly brain-penetrant, oral NLRP3 inhibitor, and expect to initiate Phase 1 study in...

NMRA : 2.47 (unch)
Neumora Therapeutics to Participate in Upcoming Conferences in November

WATERTOWN, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven programs that...

NMRA : 2.47 (unch)
Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-898

NMRA-898 is structurally distinct from NMRA-861 and is the second M4 PAM in Neumora’s M4 franchise; both programs have potential best-in-class pharmacology No convulsions observed in pre-clinical...

NMRA : 2.47 (unch)
Neumora Therapeutics to Host Virtual R&D Day on October 27

WATERTOWN, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven programs that...

NMRA : 2.47 (unch)
Neumora Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Initiated Phase 1 single-ascending dose/multiple-ascending dose (SAD/MAD) study with M4 positive allosteric modulator (PAM) NMRA-861, with data expected in the first quarter of 2026 Announces...

NMRA : 2.47 (unch)

Business Summary

Neumora Therapeutics Inc. is a clinical-stage biopharmaceutical company. Its therapeutic pipeline currently consists of clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Neumora...

See More

Key Turning Points

3rd Resistance Point 2.64
2nd Resistance Point 2.58
1st Resistance Point 2.53
Last Price 2.47
1st Support Level 2.41
2nd Support Level 2.35
3rd Support Level 2.30

See More

52-Week High 3.65
Fibonacci 61.8% 2.49
Last Price 2.47
Fibonacci 50% 2.13
Fibonacci 38.2% 1.77
52-Week Low 0.61

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.